Last updated: August 14, 2025
Introduction
Patent AU2017274110, titled "Methods for Treating or Preventing Respiratory Diseases," was granted by the Australian Patent Office in 2018. This patent addresses innovative therapeutic approaches for respiratory conditions, particularly implying modulation of immune responses through specific pharmaceutical compositions. The scope and claims define the patent's strength and influence within the global and local patent landscapes, impacting R&D strategies and licensing opportunities for pharmaceutical entities.
This analysis provides an in-depth review of the patent’s scope, deciphering claim language, exploring its patent landscape, and assessing its commercial and legal positioning within the medicinal patent ecosystem in Australia and globally.
Scope of Patent AU2017274110
Summary of the Patent Content
The patent’s core revolves around novel methods for treating or preventing respiratory diseases Leveraging immunomodulatory compounds targeting specific pathways. The inventors focus on pharmaceuticals capable of modulating immune responses, particularly through the administration of biologically active molecules such as antibodies or small molecules that influence cytokine pathways relevant to respiratory illnesses like asthma, COPD, or viral infections such as influenza and COVID-19.
The patent emphasizes:
- Pharmaceutical compositions comprising specific immunomodulatory agents.
- Use of these compositions for treating respiratory diseases characterized by inflammatory or immune-mediated pathologies.
- Administration protocols, doses, and formulations enhancing therapeutic efficacy.
Claim Scope Analysis
Patent AU2017274110’s claims can be grouped into two categories, typical of pharmaceutical patents: "composition claims" and "use claims." A close reading indicates a strategic focus on method claims, which under Australian patent law provide broad protection, especially if claiming a novel therapeutic application.
Key Claims and Their Scope:
-
Claim 1 (Method of Treatment):
"A method of treating a respiratory disease in a subject in need thereof, comprising administering an effective amount of a pharmaceutical composition comprising [specific immunomodulatory agent], wherein the respiratory disease is characterized by [specific biomarker or pathology]."
Scope: Very broad, covering any respiratory disease where the specified agent is effective, without specificity to the disease severity or patient subtype.
-
Dependent Claims (Claims 2-10):
These specify features such as dosage regimen, timing, combination therapies, and routes of administration. They narrow the scope but do not diminish the broadness of the independent claim.
-
Use Claims:
Covering the application of compositions for specific diseases, e.g., asthma, COPD, or viral infections like COVID-19.
The claims appear to focus on a therapeutic method of administering the specified immunomodulatory agent for respiratory ailments, emphasizing novelty in disease indication and method of use.
Strength and Limitations of Scope
-
Strengths:
The broad claim language encompasses various respiratory diseases and multiple administration protocols, allowing expansive licensing or enforcement options.
-
Limitations:
Patentability may rely heavily on demonstrating novelty, inventive step, and non-obviousness concerning existing immunotherapy patents. Australian law requires novelty over prior art, and broad claims may be challenged if similar methods exist. Additionally, the patent's scope may be limited if prior art discloses similar immunomodulatory treatments for respiratory diseases.
Patent Landscape in Australia and Global Context
Australian Patent Landscape
Australia’s patent environment for pharmaceuticals is notably competitive, with a focus on innovations in immunotherapy, biologics, and respiratory disease management.
- Major Patent Families: Several Australian patents cover corticosteroid formulations, biologics targeting cytokines such as IL-5, IL-13, or IL-4, and gene therapy approaches for respiratory diseases.
- Relevance of AU2017274110:
Its emphasis on novel use and method claims for immunomodulation aligns with the current Australian trend of method patents securing market exclusivity amidst a crowded biologics patent landscape.
Global Patent Landscape
-
Similar Approaches:
Numerous patents globally aim to treat respiratory diseases through cytokine modulation, including the use of monoclonal antibodies like omalizumab, mepolizumab, and dupilumab.
-
Key International Patent Filings:
Several related patents filed through the Patent Cooperation Treaty (PCT), especially at the World Intellectual Property Organization (WIPO), aim to cover similar use cases, with claims directed to immunotherapeutic methods for respiratory diseases.
-
Challenges and Opportunities:
Competing patents may limit freedom to operate, particularly where biologics targeting inflammatory cytokines have achieved prior patent protection. The novelty of AU2017274110 suggests it may carve out niche claims, especially if it introduces unique compounds or specific combination therapies.
Patent Expiry and Lifespan
- Given its filing in 2017 and patent term rights, the patent is expected to expire around 2037, considering adjustments for patent term extensions where applicable. This timing affects strategic positioning for commercial development and potential generic entry.
Implications for Stakeholders
Pharmaceutical Companies and Innovators
- The broad scope of method claims offers a formidable barrier to generic competition in the Australian market.
- Careful patent landscape navigation is necessary to avoid infringement of existing biologics patents.
- Identifying unique aspects, such as specific biomarker-driven indications, enhances enforceability.
Licensing and Commercialization
- The patent provides a foundation for licensing expositions, especially in combination therapies or personalized medicine applications.
- Opportunities exist to expand claims through subsequent filings, e.g., divisional applications or supplementary protection certificates.
Research and Development Dynamics
- The patent underscores the importance of targeted immunomodulation strategies in respiratory disease management.
- Researchers should monitor the evolving patent landscape for competing claims or potential infringements.
Key Takeaways
-
Broader Claims Drive Strategic Value:
The patent’s method claims provide extensive protection over respiratory disease treatments via immunomodulation, positioning the patent as a valuable asset in the biologics sector.
-
Competitiveness in the Australian Market:
Patent AU2017274110 aligns with Australia’s trend towards protecting innovative immunotherapy methods, but must be carefully navigated amidst existing patent activity.
-
Global Patent Positioning Matters:
Similar international patents suggest a crowded landscape; thus, detailed novelty and inventive step assessments are critical to defend or expand the patent’s scope.
-
Patent Lifecycle and Commercial Opportunities:
Strategic planning around patent expiry and subsequent filings can enhance long-term value, especially if new indications or compounds are developed.
-
Legal and Commercial Vigilance:
Given the complexity of biologic and immunotherapy patents, continuous monitoring and legal due diligence are essential for effective enforcement and licensing strategies.
FAQs
1. What is the primary innovation claimed by AU2017274110?
The patent claims a therapeutic method involving administering specific immunomodulatory agents to treat or prevent respiratory diseases, emphasizing particular compositions and treatment protocols.
2. How does this patent impact generic drug development in Australia?
Its broad method claims could delay generic entry in the specified indications by asserting patent rights over the treatment methods, though generic manufacturers may explore around claims or challenge patent validity.
3. Are there similar patents internationally?
Yes. Many patents worldwide focus on biologics targeting cytokine pathways for respiratory diseases, such as IL-5 or IL-13 inhibitors, which may overlap with or challenge the scope of AU2017274110.
4. What strategies can patentees use to strengthen their patent portfolio around this technology?
Filing divisional applications, supplementary protection certificates, or expanding claims to specific compounds, formulations, or biomarkers can enhance protection.
5. When does the patent expire, and what implications does this have?
Expected expiration around 2037, influencing market exclusivity, licensing negotiations, and R&D planning for the next-generation therapies.
References
[1] Australian Patent AU2017274110, "Methods for Treating or Preventing Respiratory Diseases."
[2] World Intellectual Property Organization (WIPO). List of patents related to immunotherapy for respiratory diseases.
[3] Australian Patent Office. Guidelines on method claims and patentability criteria.
[4] Relevant literature on cytokine-targeting biologics and their patent landscapes.
In conclusion, AU2017274110 represents a strategically significant patent in the immunotherapy space for respiratory diseases, with broad claims that align with current therapeutic trends but require careful navigation within an active patent landscape to maximize commercial and legal advantages.
